Medtronic Raises 2027 Forecasts Amid Heart Device Demand Surge

Medtronic has revised its fiscal 2027 outlook, projecting higher revenue growth due to increased demand for its heart devices used in complex cardiovascular procedures. The company anticipates annual organic revenue growth between 7.25% and 7.75%, up from its previous estimate of 6.75% to 7.25%.

Strategic Investments and Market Expansion

The company announced significant investments, including $80 million in Pi-Cardia, a heart-valve repair device manufacturer, with an option to acquire it for $210 million. Additionally, Medtronic invested $700 million in Cornerstone Robotics, securing distribution rights for a robotic surgical device in select international markets. CEO Geoff Martha emphasized the potential of Cornerstone's Sentire device in complementing Medtronic's existing Hugo system, particularly in emerging markets where soft tissue robotic surgery adoption is less than 1%.

Financial Performance and Projections

Medtronic's recent financial performance has bolstered its confidence in the revised forecasts. In the latest quarter, the company's cardiovascular segment saw a 19.5% increase in sales, reaching $3.93 billion. This growth was largely driven by an 88% rise in sales from its pulsed field ablation portfolio, used to treat irregular heart rhythms. The company reported an adjusted quarterly profit of $1.45 per share on $9.76 billion in revenue, surpassing analysts' expectations of $1.39 per share on $9.55 billion in revenue, according to LSEG data.

Medtronic's financial chief, Thierry Pieton, noted that the company received tariff refunds covering nearly all duties paid during the quarter. However, these refunds have not been factored into future financial projections.

Focusing on Growth Segments

Martha highlighted Medtronic's strategic focus on high-growth segments within the medtech industry, targeting areas with large patient populations and significant market potential. "We've had a steady cadence of M&A, prioritizing segments where we see robust growth opportunities," Martha stated.

Medtronic's decision to adjust its fiscal outlook reflects confidence in its diverse business performance and the impact of new growth platforms. As the demand for advanced medical technologies rises, Medtronic is positioning itself to capitalize on these trends through strategic investments and market expansion.